

# Structure modification

homology, analogy, isomeres,  
izosteres

Tomáš Goněc

# Lead compounds

- biological effect

origin:

- local folk remedies
- natural products
- discovered by accident (often unexpected side effects)
- intrinsic signal molecules  
(neurotransmitters, peptide hormones)

# Analogy-based drug research

aim to achieve better properties

- toxicity
- stability
- bio-availability
- side effects
- biological half-time (elimination pathway)



# Structure-activity relationships (SAR)

optimization of the structure  
similar structures = similar properties

pharmacophore = parts of structure  
necessary for biological effect

# ISOMERES

- proteins and macromolecules are assymetrical in nature
- compound-target interaction is determined by its three-dimensional orientation




# Enantiomeres

= isomeres with three-dimensional arrangement of atoms(groups) like mirror images


= chiral compounds, antipods, enantiomorphs

- identic physicochemical properties


except of ability to rotate polarized light rays (optical activity)




## ENANTIOMERS




*S*-(+)-naproxen sodium




*R*-(-)-naproxen sodium



Levorphanol (analgesic)



Dextrophan (antitussive)



*R*-(-)-Epinephrine

*S*-(+)-Epinephrine

*N*-Methyldopamine




# Diastereoisomers


= all stereoisomeric compounds that are not enantiomers

- structures containing substituted
  - double bonds
  - ring systems
  - more than one chiral centrum
- have different physicochemical properties


## DIASTEREOISOMERS




1*R*, 2*S*-(-)-Ephedrine




1*R*, 2*R*-(-)-Pseudoephedrine




*Z*-triprolidine (inactive)




*E*-triprolidine (active)







Isomethadol




Morphine



Chloramphenicol



Labetalol




Enalapril


# HOMOLOGY

increasing number of methylene groups  
= increasing lipophilicity

low lipophilicity (hydrophilicity)  
= poor membrane penetration


high lipophilicity  
= poor biodistribution, accumulation in  
adipose tissues





Size	IC <sub>50</sub> (nM)
n = 2	19,000
n = 3	1,700
n = 4	19
n = 5	4.8
n = 6	8.1

**Fig. 12.2** Angiotensin-convertase inhibiting potency of enalaprilat analogues.<sup>4</sup>




---

Blood pressure in the cat

---


R	Hypertensive	Hypotensive
Hydrogen	++	-
Methyl	++	-
Ethyl	+	+
Propyl	-	+
Isopropyl	-	++
Butyl	-	++
Isobutyl	-	++

---





# ANALOGY

removal of double bonds increase flexibility




introduction or removal of ring systems changes overall size of the molecule






**Benzylpenicillin (not  $\beta$ -lactamase resistant)**





**2-Phenylbenzylpenicillin (not  $\beta$ -lactamase resistant)**




**Diphenicillin ( $\beta$ -lactamase resistant)**

some parts of natural compounds are not necessary for the effect and/or are responsible for side effects







**Levorphanol**




**Morphine**



**Pethidine**



**Pentazocine**



**Methadone**

# **ISOSTERES**

isosteric groups exhibit similarities in chemical and physical properties

## **Classical isosteres**

- atoms, ions and molecules with identical outer shells of electrons

$-\text{CH}_3, -\text{NH}_2, -\text{OH}, -\text{F}, -\text{Cl}.$

$-\text{Cl}, -\text{SH}, -\text{PH}_2$

$-\text{Br}, \text{isopropyl } \begin{array}{c} \text{CH}_3 \\ | \\ -\text{CH} \\ | \\ \text{CH}_3 \end{array}$

$-\text{CH}_2-, -\text{NH}-, -\text{O}-, -\text{S}-$

$-\text{COCH}_2\text{R}, -\text{CONHR}, -\text{COOR}, -\text{COSR}$

$-\text{HC}=\text{C}, -\text{N}=\text{N}$

*In rings:*  $-\text{CH}=\text{CH}-, -\text{S}-$

$-\text{O}-, -\text{S}-, -\text{CH}_2-, -\text{NH}-$

$-\text{CH}=\text{C}, -\text{N}-$

## Monovalent bioisosteres

F, H

OH, NH

F, OH, NH or  $\text{CH}_3$  for H

SH, OH

Cl, Br,  $\text{CF}_3$

## Divalent bioisosteres:

$\text{—C=S}$ ,  $\text{—C=O}$ ,  $\text{—C=NH}$ ,  $\text{—C=C—}$

## Trivalent atoms or groups:


$\text{—}\underset{\text{H}}{\text{C}}\text{=}$  ,  $\text{—N=}$

$\text{—P=}$  ,  $\text{—As=}$

## Tetrasubstituted atoms:




## Ring equivalents:







# Bioisosteres

- groups with similar biological activity







GABA




isoguvacine




THIP




cimetidine




ranitidine



roxatidine



famotidine




nizatidine


**Table 1.1** Comparison of approximately equivalent daily doses of H<sub>2</sub>-receptor antagonists.

Drug	Daily dose (mg)	Molecular weight (Da)
cimetidine	800	252
nizatidine	300	331
ranitidine	300	314
roxatidine	150	385 <sup>a)</sup>
famotidine	40	337


a) Administered as acetate hydrochloride.




simvastatin



pravastatin




rosuvastatin




atorvastatin

Table 1.2 Inhibitory effects of various statins *in vitro*.


Drug	IC <sub>50</sub> (nM)	Molecular weight (Da)
pravastatin	44.1	424
simvastatin	11.2	419
atorvastatin	8.2	559
rosuvastatin	5.4	482




cisplatin




carboplatin



oxaliplatin



benzylpenicillin



ampicillin, R = H

amoxicillin, R = OH






Figure 1.16 Structures of ACE inhibitors.

**Table 1.4** Elimination half-life values of ACE inhibitors [31].

Drug	Elimination half-life (h)
captopril	2
benazepril	11
cilazapril	10
enalapril	11
fosinopril	12
lisinopril	12
perindopril	>24
ramipril	8–14
trandolapril	16–24